# Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC

> **NCT05894889** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Peking University** · enrollment: 70 (estimated)

## Conditions studied

- Stage IIIB(N2) Non-small Cell Lung Cancer
- Stage IIA Non-small Cell Lung Cancer
- Stage IIB Non-small Cell Lung Cancer
- Stage IIIA Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Pembrolizumab 200 mg IV infusion

## Key facts

- **NCT ID:** NCT05894889
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-30
- **Primary completion:** 2027-08-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-07-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05894889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05894889, "Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05894889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*